このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

再発または難治性マントル細胞リンパ腫の治療のための修飾免疫細胞 (CD19 CAR T 細胞) および Acalabrutinib

2026年9月30日 更新者:City of Hope Medical Center

再発または難治性マントル細胞リンパ腫 (MCL) 患者を対象に、アカラブルチニブと組み合わせた CD19 特異的キメラ抗原受容体 (CAR)-T 細胞を評価する第 2 相試験

This phase II trial investigates the side effects of CD19 chimeric antigen receptor (CAR) T cells and acalabrutinib, and to see how well they work in treating patients with mantle cell lymphoma that has come back (relapsed) or does not respond to treatment (refractory). T cells are infection fighting blood cells that can kill cancer cells. The T cells given in this study will come from the patient and will have a new gene put in them that makes them able to recognize CD19, a protein on the surface of the cancer cells. These CD19-specific T cells may help the body's immune system identify and kill CD19 positive cancer cells. Acalabrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving CD19 CAR T cells together with acalabrutinib may kill more cancer cells.

調査の概要

詳細な説明

PRIMARY OBJECTIVES:

I. Evaluate the safety of adding CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes (CD19 CAR T cells) to acalabrutinib treatment. (Safety Lead-in) II. Estimate the complete response (CR) rate within 6 months after adding CD19 CAR T cells to acalabrutinib treatment. (Phase 2)

SECONDARY OBJECTIVES:

I. Assess best response, time to and duration of CR. II. Estimate the 1-year progression free survival (PFS) rate and overall survival (OS).

III. Describe the full toxicity profile.

EXPLORATORY OBJECTIVES:

I. Assess CD19-CAR T cell persistence. II. Assess CD19-CAR T cell activity as measured by CD19 B cell aplasia. III. Describe the duration of CR from completion of acalabrutinib. IV. Describe immunogenicity of CD19-CAR T cells in the presence of the BTK inhibitor.

V. Characterize CD19 expression on tumor cells. VI. Describe cytokine profile after CD19-CAR T cell infusion. VII. Determine BTK and PLCG2 mutational status prior to treatment.

OUTLINE:

Patients receive acalabrutinib orally (PO) twice daily (BID) on days -5 to 28 of cycle 1 and on days 1-28 of subsequent cycles. Patients also receive CD19 CAR T cells intravenously (IV) on day 0. Treatment with acalabrutinib repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients who have not attained CR after the first disease assessment and tolerated the initial CAR T cell infusion may receive a second CAR T cell infusion in cycle 2.

After completion of study treatment, patients are followed up at 3, 6 and 12 months, then yearly for up to 15 years post CAR T cells infusion.

研究の種類

介入

入学 (推定)

36

段階

  • フェーズ2

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • California
      • Duarte、California、アメリカ、91010
        • City of Hope Comprehensive Cancer Center

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年~75年 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria Informed Consent and Willingness to Participate

  1. All participants must have the ability to understand and the willingness to sign a written informed consent.

  2. Participants must agree to allow the use of archival tissue from diagnostic tumor biopsies.

    • If unavailable, exceptions may be granted with Study PI approval. Note: For research participants who do not speak English, a short form consent may be used with a COH certified interpreter/translator to proceed with screening and leukapheresis, while the request for a translated full consent is processed.

    Age Criteria

  3. Age 18 years and older. Performance Status

  4. ECOG Performance status ≤ 2 or KPS ≥ 70% (Appendix A) Nature of Illness and Treatment-Related Criteria

  5. Documented CD19+ MCL by flow cytometry or IHC (from biopsy) if prior CD19 directed therapy was previously used

    a. BM is optional at enrollment IF patient already has biopsy proven disease.

  6. Participants must be currently receiving acalabrutinib and have been taking acalabrutinib for between 3 and 7 months prior to initiating screening procedures on the study and:

    1. must have at least 1 prior regimen (not including single-agent corticosteroids)
    2. best response to acalabrutinib therapy is MRD+ CR, PR or SD at the time of screening b (1) must have measurable disease by CT scan (≥ 1.5 cm) or evidence of blood, spleen, skin, gastrointestinal (GI) or bone marrow involvement Note: Participants who are on other BTK inhibitors, but will thereafter be switched to acalabrutinib prior to lymphodepletion, may be eligible provided that the duration of all BTK inhibitor therapy was ≤ 3-7 months
  7. No contraindications to leukapheresis, steroids or tocilizumab Clinical Laboratory Criteria (To be performed within 28 days prior to enrollment)

  8. Total serum bilirubin ≤ 2.0 mg/dL Participants with Gilbert syndrome may be included if their total bilirubin is ≥ 3.0 x ULN and direct bilirubin ≤ 1.5 x ULN.

  9. Blood counts:

    • Absolute Neutrophil count (ANC ≥1000 cells/ul)*

      • Growth factor use within 7 days prior screening is not allowed
    • Platelet count ≥75,000/ul. Transfusion with 7 days prior to screening is not allowed* *Exception: participants with bone marrow involvement do not need to meet this criteria

  10. AST < 3 x ULN

  11. ALT < 3 x ULN

  12. Creatinine clearance of ≥ 50 mL/min per the Cockcroft-Gault formula

  13. International Normalized Ratio (INR) OR Prothrombin (PT) ≤ 1.5 x ULN

  14. Activated Partial Thromboplastin Time (aPTT) ≤ 1.5 x ULN

  15. Female of childbearing potential: negative urine or serum pregnancy test. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required

  16. Cardiac function (12 lead-ECG): QTc must be ≤ 480 msec

  17. Left ventricular ejection fraction >40%

  18. Oxygen saturation 92% or above at room air or DLCO of 40% of best predicted Contraception

  19. Participants of reproductive potential must agree to use highly effective birth control methods throughout therapy and for 2 months after final CAR T cell infusion and/or 2 days after final acalabrutinib dose, whichever is later (See Section 5.12 and Appendix B).

Exclusion Criteria Previous therapies

  1. Allogeneic hematopoietic cell transplantation (HCT) within the last 6 months.

  2. Autologous HCT within the last 3 months.

  3. Prior failure of any BTK inhibitor therapy. (Participant WILL be allowed if, after administration of other BTK inhibitors they have switched to acalabrutinib prior to lymphodepletion, and if the duration of all BTK inhibitor therapy was ≤ 3-7 months).

  4. Participants known to have mutations associated with resistance to BTK inhibitors from prior studies.

    Concomitant therapies

  5. Concurrent use of systemic steroids or chronic use of immunosuppressant medications. Recent or current use of inhaled steroids is not exclusionary. Physiologic replacement of steroids (i.e., prednisone ≤ 7.5 mg /day, or hydrocortisone ≤ 20 mg /day) is allowed. During study participation, participants may receive systemic corticosteroids as needed for treatment-emergent comorbid conditions.

  6. Approved anti-cancer therapies other than acalabrutinib are not allowed after enrollment, with the exception of steroids or involved field radiation to control progressive disease during cell manufacturing, prior to lymphodepletion/start of protocol therapy.

  7. Requires treatment with a strong cytochrome P450 3A4 (CYP3A4) inhibitor/inducer.

  8. Unable to discontinue anticoagulation with warfarin or equivalent vitamin K antagonists (e.g., phenprocoumon) within 7 days of leukapheresis and remain off through end of study treatment.

    Other illnesses or conditions

  9. Class III/IV cardiovascular disability according to the New York Heart Association Classification. Subjects with controlled, asymptomatic atrial fibrillation can enroll.

  10. Participants with clinically significant arrhythmia or arrhythmias not stable on medical management.

  11. Active auto-immune disease requiring systemic immunosuppressive therapy, including uncontrolled autoimmune hemolytic anemia (AIHA) or idiopathic thrombocytopenic purpura (ITP).

  12. Suspected or confirmed progressive multifocal leukoencephalopathy (PML).

  13. Requires major surgical procedure within 28 days prior to first dose of study drug. If a subject has major surgery, they must have recovered adequately from any toxicity and/or complications from the intervention before the first dose of study drug.

  14. Participants with a known history or prior diagnosis of optic neuritis or other immunologic or inflammatory disease affecting the central nervous system.

  15. Known history of drug-specific hypersensitivity or anaphylaxis to either study agent.

  16. Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel that is likely to affect absorption, symptomatic inflammatory bowel disease, partial or complete bowel obstruction, or gastric restrictions and bariatric surgery, such as gastric bypass.

  17. Known bleeding disorders (e.g., von Willebrand's disease or hemophilia)

  18. History of stroke or intracranial hemorrhage within 6 months prior to enrollment.

  19. History of other malignancies, except for the following: malignancy surgically resected (or treated with other modalities) with curative intent, adequately treated in situ carcinoma of the breast or cervix uteri, basal cell carcinoma of the skin or localized squamous cell carcinoma of the skin; early stage prostate cancer on expectant management; malignancy treated with curative intent with no known active disease present for ≥ 3 years.

  20. Lactating women.

  21. Active chronic graft-versus-host disease (GVHD) post-allogeneic HCT.

  22. Uncontrolled active infection:

    • HIV positive or have active hepatitis B or C infection based on testing performed within 4 weeks of enrollment.
    • Hepatitis B or C serologic status: subjects who are hepatitis B core antibody (anti-HBc) positive and who are surface antigen negative will need to have a negative polymerase chain reaction (PCR) result. Those who are hepatitis B surface antigen (HbsAg) positive or hepatitis B PCR positive will be excluded.
    • Subjects who are hepatitis B core antibody positive (or have a known history of HBV infection) should be monitored quarterly with a quantitative PCR test for HBV DNA. HBV monitoring should last until 12 months after last dose of study drug. Any subject with a rising viral load (above lower limit of detection) should discontinue study drug and have antiviral therapy instituted and a consultation with a physician with expertise in managing hepatitis B. Subjects who are core Ab positive at study enrollment are strongly recommended to start Entecavir before start and until completion of study treatment.
    • Subjects who are hepatitis C antibody positive will need to have a negative PCR result. Those who are hepatitis C PCR positive will be excluded.
    • Subjects who are positive cytomegalovirus [CMV] DNA polymerase chain reaction [PCR]).
    • Subject with any active significant bacterial, fungal or viral (other than those listed) infections.
  23. Any other condition that would, in the Investigator's judgment, contraindicate the subject's participation in the clinical study due to safety concerns with clinical study procedures.

    Noncompliance

  24. Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics).

    • Eligibility should be confirmed per institutional policies.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:なし
  • 介入モデル:単一グループの割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Treatment (CD19 CAR T cells, acalabrutinib)

Patients receive acalabrutinib PO BID on days -5 to 28 of cycle 1 and on days 1-28 of subsequent cycles. Patients also receive CD19 CAR T cells IV on day 0. Treatment with acalabrutinib repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients who have not attained CR after the first disease assessment and tolerated the initial CAR T cell infusion may receive a second CAR T cell infusion in cycle 2.

Given PO

他の名前:
  • 計算
  • ACP-196
  • Bruton チロシンキナーゼ阻害剤 ACP-196

Given IV

他の名前:
  • CD19R(EQ)28zetaEGFRt+ Tn/mem 細胞
  • CD19CAR-CD28-CD3zeta-EGFRt 発現 Tn/mem 濃縮 T 細胞
  • CD19R(EQ)28zeta/EGFRt+ ナイーブおよびメモリー T 細胞

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Occurrence of dose-limiting toxicities (DLTs) (Safety Lead-in)
時間枠:Day 0 up to 28 days after the first chimeric antigen receptor (CAR) T cell infusion

Rates and associated 95% Clopper and Pearson exact confidence interval (CI) will be estimated for DLTs at the safe dose.

Day 0 up to 28 days after the first chimeric antigen receptor (CAR) T cell infusion
Complete response (CR) (Phase II)
時間枠:Within 6 months of CAR T-cell infusion and concurrent acalabrutinib therapy

Response will be assessed based on Lugano classification. CR rate is defined as the proportion of response-evaluable participants who achieve a best response of CR within 6 months of CAR T-cell infusion and concurrent acalabrutinib therapy. Rates and associated 95% Clopper and Pearson exact CI will be estimated for CR within 6 months.

Within 6 months of CAR T-cell infusion and concurrent acalabrutinib therapy

二次結果の測定

結果測定
メジャーの説明
時間枠
Time to CR
時間枠:From the first achievement of CR after CAR T cell infusion through disease relapse or progression or death, assessed up to 15 years

Descriptive statistics will be used to summarize the time to CR among those who achieve CR.

From the first achievement of CR after CAR T cell infusion through disease relapse or progression or death, assessed up to 15 years
Duration of CR
時間枠:From the first achievement of CR after CAR T cell infusion through disease relapse or progression or death, assessed up to 15 years

Duration of CR will be assessed using Kaplan Meier methods.

From the first achievement of CR after CAR T cell infusion through disease relapse or progression or death, assessed up to 15 years
Best response
時間枠:Up to 1 year post CAR T cell infusion

Defined as the best response documented at any time after CAR T cell infusion through 1 year after CAR T cell infusion or the start of any non-protocol anti-lymphoma therapy, whichever occurs first. Best response will be presented in tabular format including counts and percentages.

Up to 1 year post CAR T cell infusion
Progression-free survival (PFS)
時間枠:From start of protocol treatment (start of lymphodepletion) to the first observation of disease relapse/progression or death due to any cause, whichever occurs first, assessed at 1 year

Progression-free survival will be assessed using Kaplan Meier methods.

From start of protocol treatment (start of lymphodepletion) to the first observation of disease relapse/progression or death due to any cause, whichever occurs first, assessed at 1 year
Overall survival (OS)
時間枠:From start of protocol treatment (start of lymphodepletion) to death due to any cause, assessed at 1 year

OS will be assessed using Kaplan Meier methods.

From start of protocol treatment (start of lymphodepletion) to death due to any cause, assessed at 1 year
Incidence of adverse events
時間枠:Up to 15 year post CAR T cell infusion

Toxicities will be recorded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version (v) 5. Observed toxicities will be summarized by type, severity, date of onset (per each treatment cycle or follow-up period), and attribution.

Up to 15 year post CAR T cell infusion

その他の成果指標

結果測定
メジャーの説明
時間枠
CD19 CAR T cell persistence
時間枠:At 28 days

Rates and associated 95% Clopper and Pearson exact CI will be estimated for CD19 CAR T cell persistence at 28 days.

At 28 days
Presence of CD19CAR immunogenicity
時間枠:Up to 1 year post CAR T cell infusion

Rates and associated 95% Clopper and Pearson exact CI will be estimated for presence of CD19CAR immunogenicity.

Up to 1 year post CAR T cell infusion
Duration of CR from completion of acalabrutinib
時間枠:Up to 15 years post CAR T cell infusion

This analysis will include only participants who have achieved CR and completed 6 cycles of acalabrutinib, and it will be defined as the time from last dose of acalabrutinib through disease relapse, progression or death, whichever is earlier. Will be assessed using Kaplan Meier methods.

Up to 15 years post CAR T cell infusion

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Lihua E Budde、City of Hope Medical Center

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2020年12月31日

一次修了 (推定)

2027年2月23日

研究の完了 (推定)

2027年2月23日

試験登録日

最初に提出

2020年7月7日

QC基準を満たした最初の提出物

2020年7月21日

最初の投稿 (実際)

2020年7月23日

学習記録の更新

投稿された最後の更新 (実際)

2026年10月1日

QC基準を満たした最後の更新が送信されました

2026年9月30日

最終確認日

2026年9月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • 19405
  • P30CA033572 (米国 NIH グラント/契約)
  • 19405 (その他の識別子:City of Hope Comprehensive Cancer Center)
  • NCI-2020-04550 (レジストリ識別子:CTRP (Clinical Trial Reporting Program))

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

米国で製造され、米国から輸出された製品。

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する